IntelliEPI Cayman Cash Flow Conversion Efficiency
IntelliEPI Cayman cash flow conversion efficiency. Based on the latest financial reports, IntelliEPI Cayman (4971) has a cash flow conversion efficiency ratio of 0.015x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$30.51 Million ≈ $961.36K USD) by net assets (NT$2.09 Billion ≈ $65.96 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of IntelliEPI Cayman (2011–2025)
Cash flow conversion efficiency of IntelliEPI Cayman from 2011 to 2025. This chart illustrates how IntelliEPI Cayman's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for IntelliEPI Cayman for real-time trading data and today's change.
IntelliEPI Cayman Cash Flow Conversion Ratio Explained
IntelliEPI Cayman cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
IntelliEPI Cayman Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of IntelliEPI Cayman ranked by their cash flow conversion efficiency. Also see market cap of IntelliEPI Cayman for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CREDIT CORP. GROUP LTD.
F:2RC
|
N/A |
|
Amper S.A.
MC:AMP
|
-0.602x |
|
CellaVision AB
ST:CEVI
|
0.058x |
|
Pony Testing International Group Co
SHE:300887
|
0.041x |
|
Qinghai Huzhu Barley Wine Co Ltd
SHE:002646
|
0.000x |
|
Raisecom Technology Co Ltd
SHG:603803
|
-0.004x |
|
Everjoy Health Group Co Ltd
SHE:002162
|
0.048x |
|
TPI Polene Public Company Limited
BK:TPIPL
|
0.015x |
Annual Cash Flow Conversion Efficiency for IntelliEPI Cayman (2011–2025)
The table below shows the annual cash flow conversion efficiency of IntelliEPI Cayman from 2011 to 2025. Review 4971 cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$2.02 Billion ≈ $63.56 Million |
NT$234.84 Million ≈ $7.40 Million |
0.116x | +1094.63% |
| 2024-12-31 | NT$1.76 Billion ≈ $55.47 Million |
NT$17.16 Million ≈ $540.54K |
0.010x | -82.17% |
| 2023-12-31 | NT$1.66 Billion ≈ $52.34 Million |
NT$90.79 Million ≈ $2.86 Million |
0.055x | -61.97% |
| 2022-12-31 | NT$1.73 Billion ≈ $54.39 Million |
NT$248.12 Million ≈ $7.82 Million |
0.144x | -5.94% |
| 2021-12-31 | NT$1.45 Billion ≈ $45.79 Million |
NT$222.07 Million ≈ $7.00 Million |
0.153x | +171.37% |
| 2020-12-31 | NT$1.40 Billion ≈ $44.08 Million |
NT$78.78 Million ≈ $2.48 Million |
0.056x | -40.92% |
| 2019-12-31 | NT$1.46 Billion ≈ $46.09 Million |
NT$139.43 Million ≈ $4.39 Million |
0.095x | -1.28% |
| 2018-12-31 | NT$1.46 Billion ≈ $46.10 Million |
NT$141.27 Million ≈ $4.45 Million |
0.097x | -23.87% |
| 2017-12-31 | NT$1.44 Billion ≈ $45.26 Million |
NT$182.17 Million ≈ $5.74 Million |
0.127x | -5.90% |
| 2016-12-31 | NT$1.49 Billion ≈ $46.83 Million |
NT$200.31 Million ≈ $6.31 Million |
0.135x | -22.23% |
| 2015-12-31 | NT$1.48 Billion ≈ $46.71 Million |
NT$256.94 Million ≈ $8.10 Million |
0.173x | +1840.45% |
| 2014-12-31 | NT$1.00 Billion ≈ $31.61 Million |
NT$8.96 Million ≈ $282.32K |
0.009x | -76.48% |
| 2013-12-31 | NT$800.25 Million ≈ $25.21 Million |
NT$30.39 Million ≈ $957.48K |
0.038x | -88.64% |
| 2012-12-31 | NT$486.27 Million ≈ $15.32 Million |
NT$162.49 Million ≈ $5.12 Million |
0.334x | +49.70% |
| 2011-12-31 | NT$423.95 Million ≈ $13.36 Million |
NT$94.64 Million ≈ $2.98 Million |
0.223x | -- |
About IntelliEPI Cayman
IntelliEPI Inc. (Cayman), together with its subsidiaries, produces and sells epitaxy wafers of compound semiconductor for use in wireless communications, data transmission and national defense in the United States, Germany, Korea, Japan, China, and internationally. The company utilizes its proprietary real-time in situ growth monitoring technology on molecular beam epitaxy (MBE) systems for the m… Read more